Less than six months after Nasdaq debut, Malaysia’s Alps Group pivots to bridge biotech access gap
It is expanding into insurance and education to rebuild valuation and put advanced treatments within reach for more people
[KUALA LUMPUR] Less than six months after its debut on the Nasdaq, Malaysia’s Alps Group is shifting its focus from research to execution, expanding into insurance and education as it seeks to close critical gaps in access to advanced medical technologies.
Alps’ push to build a full-stack ecosystem comes as it navigates the realities of being a newly listed biotech firm.
According to US Securities and Exchange Commission filings and Nasdaq data, Alps Group is in the early stages of commercialisation, reporting 12-month trailing revenue of around US$3.7 million and has yet to achieve profitability.
TRENDING NOW
What makes a good job? Feeling that you matter
Faishal Ibrahim resigns over online messages with a female member of the public
When the disruptor gets disrupted: How Chinese open-source AI is eating its own industry
Retail resets: Mall owners reposition shopping centres as Singapore’s consumer landscape evolves
